Vous utilisez un navigateur non pris en charge.
Certaines fonctionnalités de ce site peuvent ne pas fonctionner correctement. Pour une expérience utilisateur optimale, veuillez consulter ce site en utilisant Chrome, Firefox, Safari ou Edge.

Résistance aux antimicrobiens (RAM)

Informations sur les tests
Titre générique

Webinaire et questions fréquentes sur C. difficile

C. difficile Testing with Molecular or Nucleic Acid Amplification Tests

Is Treatment the Only Issue?

C. difficile is the leading cause of gastroenteritis-associated death and is associated with approximately $5 billion in excess healthcare spending. Étant donné l’importance d’une détection précise et de la mise en place de mesures appropriées pour lutter contre les infections, le diagnostic joue un rôle essentiel dans la prise en charge des patients présentant des diarrhées cliniquement significatives.

Webinaire

Diagnosis of Clostridium difficile Infections: The Latest Poop

  • Clostridium difficile is the most common cause of health care-associated infections in U.S. hospitals and the leading cause of gastroenteritis-associated deaths. This presentation will review the evolution of laboratory tests used to diagnose Clostridium difficile infections and consider the advantages and disadvantages of current approaches. Controversies regarding potential over-diagnosis and optimal testing strategies will be discussed.

View Webinar

Questions fréquentes

C. diff Testing FAQs

Q: Who should be tested for C. difficile?

Q: Do molecular or Nucleic Acid Amplification Tests (NAAT) “overdiagnose” C. difficile?

Q: How do clinicians determine if a patient has C. difficile infection?

Q: Do all patients with CDI require treatment?

Q: Are molecular or PCR-based tests too sensitive?

Q: Should toxin immunoassays be used to determine if a patient requires treatment?

Q: Should all patients with a positive PCR-based C. difficile test be treated?

Q: Is the use of molecular assays associated with overtreatment?

Q: Will using a more-sensitive molecular C. difficile assay result in higher lab event reporting and associated penalties?

Références : 1. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31: 431-55.

2. Berry N, Sewell B, Jafri S, et al. Real-time polymerase chain reaction correlates well with clinical diagnosis of Clostridium difficile infection. J Hosp Infect. 2014;87:109-14.

3. Novak-Weekley SM, Marlowe EM, Miller JM, et al. Clostridium difficile testing in the clinical laboratory by use of multiple testing algorithms. J Clin Microbiol. 2010;48:889-93.

4. Tenover FC, Novak-Weekley S, Woods CW, et al. Impact of strain type on detection of toxigenic Clostridium difficile: comparison of molecular diagnostic and enzyme immunoassay approaches. J Clin Microbiol. 2010;48:3719-24.

5. Curry SR, Muto CA, Schlackman JL, et al. Use of multilocus variable number of tandem repeats analysis genotyping to determine the role of asymptomatic carriers in Clostridium difficile transmission. Clin Infect Dis. 2013;57:1094–102.

6. Polage CR, Gyorke CE, Kennedy MA et al. Overdiagnosis of Clostridium difficile Infection in the Molecular Test Era. JAMA Intern Med. 2015:1-10. Published online 8 septembre, 2015.

7. Planche TD, Davies KA, Coen PG, et al. Differences in outcome according to Clostridium difficile testing method: a prospective multicentre diagnostic validation study of C difficile infection. Lancet Infect Dis. 2013;13:936-45.

8. Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013;108:478-98.

9. Dubberke ER, Burnham CD. Diagnosis of Clostridium difficile Infection: Treat the Patient, Not the Test. JAMA Intern Med. 2015:1-10. Published online 8 septembre, 2015.

10. Bagdasarian N, Rao K, Malani PN. Diagnosis and treatment of Clostridium difficile in adults: a systematic review. JAMA. 2015;313(4):398-408.

11. Schroeder LF, Robilotti E, Peterson LR, et al. Economic evaluation of laboratory testing strategies for hospital-associated Clostridium difficile infection. J Clin Microbiol. 2014;52:489-96.

12. Guerrero DM, Chou C, Jury LA, et al. Clinical and infection control implications of Clostridium difficile infection with negative enzyme immunoassay for toxin. Clin Infect Dis. 2011;53:287-90.

13. Centers for Disease Control and Prevention. Frequently Asked Questions about Clostridium difficile for Healthcare Providers. Joignable au : http://www.cdc.gov/HAI/organisms/cdiff/Cdiff_faqs_HCP.html.

14. Mermel LA, Jefferson J, Blanchard K, et al. Reducing Clostridium difficile incidence, colectomies, and mortality in the hospital setting: a successful multidisciplinary approach. Jt Comm J Qual Patient Saf. 2013;39:298-305.

15. Dudeck MA, Weiner LM, Malpiedi PJ, et al. Risk Adjustment for Healthcare Facility-Onset C. difficile and MRSA Bacteremia Laboratory-identified Event Reporting in NHSN. Published 12 mars, 2013. Joignable au : http://www.cdc.gov/nhsn/pdfs/mrsa-cdi/RiskAdjustment-MRSA-CDI.pdf.

Retour en haut de page
Powered by Translations.com GlobalLink OneLink SoftwarePowered By OneLink